Drug Profile
Research programme: measles and rubella virus vaccine - Daiichi Sankyo Biotech
Latest Information Update: 30 Sep 2022
Price :
$50
*
At a glance
- Originator Kitasato Daiichi Sankyo Vaccine; Nonindustrial sources
- Developer Daiichi Sankyo Biotech
- Class Measles vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Measles; Rubella
Most Recent Events
- 30 Nov 2017 Kitasato Daiichi Sankyo Vaccine has been acquired by Daiichi Sankyo Company
- 16 Jul 2016 No recent reports of development identified for research development in Measles in Vietnam (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Rubella in Vietnam (Parenteral)